Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Human Papillomavirus (HPV) and Molecular Testing for Cervical Cancer. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Human Papillomavirus (HPV) and Molecular Testing for Cervical Cancer (online CE course) »
How to Subscribe
Individual course$20 Add to cart


APTIMA HPV 16 18/45 genotype assay. Archived content. FDA website. Available at: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm325771.htm. Accessed September 23, 2014.
ATHENA HPV clinical trial. Roche website. Available at: https://www.hpv16and18.com/hcp/athena-hpv-clinical-trial/background-study-design.html. Accessed September 23, 2014.
Basic information about cervical cancer. CDC website. Available at: http://www.cdc.gov/cancer/cervical/basic_info/. Accessed September 24, 2014.
Cervical cancer. American Cancer Society website. Available at: http://www.cancer.org/cancer/cervicalcancer/index. Accessed September 24, 2014.
Cervical cancer. National Cancer Institute website. Available at: http://www.cancer.gov/cancertopics/types/cervical. Accessed September 24, 2014.
Cervical cancer screening guidelines for average-risk women. CDC website. Available at: http://www.cdc.gov/cancer/cervical/pdf/guidelines.pdf. Accessed September 24, 2014.
Cervista HPV, Cervista HPV – Invader Technology. HOLOGIC website. Available at http://www.cervistahpv.com/laboratory/invadertechnology.html. Accessed September 24, 2014.
Cervista™ HPV HR and Genfind™ DNA Extraction Kit, FDA Approval Letter, available at: http://www.accessdata.fda.gov/cdrh_docs/pdf8/P080014a.pdf. Accessed September 24, 2014.
Cervista™ HPV 16/18, FDA Approval Letter available at: http://www.accessdata.fda.gov/cdrh_docs/pdf8/P080015a.pdf. Accessed September 24, 2014.
Check W. Data spark new directions in cervical cancer. CAP TODAY. June 2014. Available at: http://digital.olivesoftware.com/Olive/ODE/CAPTODAY/. Accessed September 8, 2014.
Check W. Study: primary HPV test 'merits consideration.' CAP TODAY. September 2014. Available at: http://digital.olivesoftware.com/Olive/ODE/CAPTODAY/. Accessed September 24, 2014.
Chin-Hong PV, Klausner JD. Diagnostic tests for HPV infection. Medical Laboratory Observer. October 2004:10-16.
Cobas4800HPVtestPackInsert. Scribd digital library. Available at: http://www.scribd.com/doc/84100610/cobas4800HPVtestPackInsert. Accessed September 24, 2014.
Cobas HPV Test,Roche Molecular Systems FDA application. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100020c.pdf. Accessed September 24, 2014.
Cobo F, Concha A, Ortiz M. Human papillomavirus (HPV) type distribution in females with abnormal cervical cytology. A correlation with histological study. Virology Journal. 2009;3:60-66.
Cox JT, Moriarty AT, CastlePE. Commentary on statement on HPV DNA test utilization. American Journal Clinical Pathology. 2009;131:770-773.
DeMay RM. Practical Principles of Cytopathology. Revised ed. Chicago, IL: American Society for Clinical Pathology Press; 2007.
Digene Hybrid Capture 2 High-Risk HPV DNA Test, FDA Approval Letter, available at: http://www.accessdata.fda.gov/cdrh_docs/pdf/p890064s009a.pdf. Accessed September 24, 2014.
Hariri S, Unger ER, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003–2006. Journal of Infectious Diseases 2011; 204(4):566–573.
HPV and cancer. National Cancer Institute Fact Sheet. Available at http://www.cancer.gov/cancertopics/factsheet/risk/hpv. Accessed September 24, 2014.
HPV Vaccine Information for Clinicians. Centers for Disease Control and Prevention. Available at http://cdc.gov/std/hpv/stdfact-hpv-vaccine-hcp.htm. Accessed September 24, 2014.
Human papilloma virus DNA detection with genotyping, high-risk types by PCR, ThinPrep. Mayo Clinic website. Available at: http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/62598. Accessed September 24, 2014.
Human Papillomavirus (HPV) Vaccines. National Cancer Institute. Available at http://www.cancer.gov/cancertopics/factsheet/prevention/HPV-vaccine. Accessed September 24, 2014.
Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology. 2011;12(7):663-672.
Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: national health and nutrition examination survey 2003-2004. Infectious Disease. 2009;200:1059-1067.
Molecular Diagnostics Fundamentals, Methods, and Clinical Applications. Leal Buckingham and Maribeth L. Flaws. Philadelphia: FA Davis Company; 2007.
Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2012; 156(12):880-91.
Rao A, Young S, Erlich H, et al. Development and characterization of the cobas HPV test. J Clin Microbiol. May 2013;51(5):1478-1484.
Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. J Low Genit Tract Dis 2012;16(3):175-204.
Schutzbank TE, Jarvis C, Kahmann N, et al. Detection of high-risk papillomavirus DNA with commercial invader-technology-based analyte-specific reagents following automated extraction of DNA from cervical brushings in Thinprep media. Journal of Clinical Microbiology. 2007;45:4067-4069.
Screening for cervical cancer. U.S Preventive Task Force. Available at: http://www.uspreventiveservicestaskforce.org/uspstf11/cervcancer/cervcancerrs.htm. Accessed September 24, 2014.
Stoler MH, Wright TC, Sharma A, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-475.
The American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists: Screening for Cervical Cancer. November, 2012.
The five FDA-approved HPV assays. MLO. July 2012. Available at: http://www.mlo-online.com/articles/201207/the-five-fda-approved-hpv-assays.php. Accessed September 24, 2014.
Updated ASCCP management guidelines. Available at: https://www.hpv16and18.com/hcp/asccp-management-guidelines.html. Accessed September 23, 2014.
Vernick JP, Steigman, CK. The HPV DNA virus hybrid capture assay: what is it—and where do we go from here? Medical Laboratory Observer. Mar 2003:8-13.
Voss JS, Kipp BR, Campion MB et al. Comparison of fluorescence in situ hybridization, hybrid capture 2 and polymerase chain reaction for the detection of high-risk human papillomavirus in cervical cytology specimens. Analytical and Quantitative Cytology and Histology. 2009;31:208-216.
What should I know about screening: Gynecologic cancers. CDC website. Available at: http://www.cdc.gov/cancer/cervical/basic_info/screening.htm. Accessed September 24, 2014.
Wright TC, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012Jan;206(1):46.e1-46.e11.
Wright TC Jr, Stoler MH, Sharma A, et al: Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV positive, cytology-negative results. Am J Clin Pathol. 2011 Oct;136(4):578-586.